152 related articles for article (PubMed ID: 17240481)
1. Interaction of NPY compounds with the rat glucocorticoid-induced receptor (GIR) reveals similarity to the NPY-Y2 receptor.
Sah R; Parker SL; Sheriff S; Eaton K; Balasubramaniam A; Sallee FR
Peptides; 2007 Feb; 28(2):302-9. PubMed ID: 17240481
[TBL] [Abstract][Full Text] [Related]
2. Characterization of a new neuropeptide Y Y5 agonist radioligand: [125I][cPP(1-7), NPY(19-23), Ala31, Aib32, Gln34]hPP.
Dumont Y; Thakur M; Beck-Sickinger A; Fournier A; Quirion R
Neuropeptides; 2004 Aug; 38(4):163-74. PubMed ID: 15337369
[TBL] [Abstract][Full Text] [Related]
3. Identification of positions in the human neuropeptide Y/peptide YY receptor Y2 that contribute to pharmacological differences between receptor subtypes.
Fällmar H; Åkerberg H; Gutiérrez-de-Terán H; Lundell I; Mohell N; Larhammar D
Neuropeptides; 2011 Aug; 45(4):293-300. PubMed ID: 21696823
[TBL] [Abstract][Full Text] [Related]
4. BIIE0246, a potent and highly selective non-peptide neuropeptide Y Y(2) receptor antagonist.
Dumont Y; Cadieux A; Doods H; Pheng LH; Abounader R; Hamel E; Jacques D; Regoli D; Quirion R
Br J Pharmacol; 2000 Mar; 129(6):1075-88. PubMed ID: 10725255
[TBL] [Abstract][Full Text] [Related]
5. Expression cloning of a human brain neuropeptide Y Y2 receptor.
Gehlert DR; Beavers LS; Johnson D; Gackenheimer SL; Schober DA; Gadski RA
Mol Pharmacol; 1996 Feb; 49(2):224-8. PubMed ID: 8632753
[TBL] [Abstract][Full Text] [Related]
6. Molecular characterization of the ligand-receptor interaction of the neuropeptide Y family.
Cabrele C; Beck-Sickinger AG
J Pept Sci; 2000 Mar; 6(3):97-122. PubMed ID: 10759209
[TBL] [Abstract][Full Text] [Related]
7. Evidence that the inhibition of luteinizing hormone secretion exerted by central administration of neuropeptide Y (NPY) in the rat is predominantly mediated by the NPY-Y5 receptor subtype.
Raposinho PD; Broqua P; Pierroz DD; Hayward A; Dumont Y; Quirion R; Junien JL; Aubert ML
Endocrinology; 1999 Sep; 140(9):4046-55. PubMed ID: 10465275
[TBL] [Abstract][Full Text] [Related]
8. Neuropeptide Y modulates effects of bradykinin and prostaglandin E2 on trigeminal nociceptors via activation of the Y1 and Y2 receptors.
Gibbs JL; Diogenes A; Hargreaves KM
Br J Pharmacol; 2007 Jan; 150(1):72-9. PubMed ID: 17143304
[TBL] [Abstract][Full Text] [Related]
9. Neuropeptide Y, Y1, Y2 and Y4 receptors mediate Y agonist responses in isolated human colon mucosa.
Cox HM; Tough IR
Br J Pharmacol; 2002 Mar; 135(6):1505-12. PubMed ID: 11906964
[TBL] [Abstract][Full Text] [Related]
10. Development and characterization of a highly selective neuropeptide Y Y5 receptor agonist radioligand: [125I][hPP1-17, Ala31, Aib32]NPY.
Dumont Y; Thakur M; Beck-Sickinger A; Fournier A; Quirion R
Br J Pharmacol; 2003 Aug; 139(7):1360-8. PubMed ID: 12890716
[TBL] [Abstract][Full Text] [Related]
11. Characterization of the cloned atlantic cod neuropeptide Y-Yb receptor: peptide-binding requirements distinct from known mammalian Y receptors.
Sharma P; Arvidsson AK; Wraith A; Beck-Sickinger AG; Jönsson-Rylander AC; Larhammar D
Gen Comp Endocrinol; 1999 Sep; 115(3):422-8. PubMed ID: 10480994
[TBL] [Abstract][Full Text] [Related]
12. Characterization of Y3 receptor-mediated synaptic inhibition by chimeric neuropeptide Y-peptide YY peptides in the rat brainstem.
Glaum SR; Miller RJ; Rhim H; Maclean D; Georgic LM; MacKenzie RG; Grundemar L
Br J Pharmacol; 1997 Feb; 120(3):481-7. PubMed ID: 9031753
[TBL] [Abstract][Full Text] [Related]
13. Identification and functional studies of a specific peptide YY-preferring receptor in dog adipocytes.
Castan I; Valet P; Voisin T; Quideau N; Laburthe M; Lafontan M
Endocrinology; 1992 Oct; 131(4):1970-6. PubMed ID: 1327725
[TBL] [Abstract][Full Text] [Related]
14. Peptide-YY and neuropeptide-Y inhibit vasoactive intestinal peptide-stimulated adenosine 3',5'-monophosphate production in rat small intestine: structural requirements of peptides for interacting with peptide-YY-preferring receptors.
Servin AL; Rouyer-Fessard C; Balasubramaniam A; Saint Pierre S; Laburthe M
Endocrinology; 1989 Feb; 124(2):692-700. PubMed ID: 2536315
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological characterization of (125)I-1229U91 binding to Y1 and Y4 neuropeptide Y/Peptide YY receptors.
Schober DA; Gackenheimer SL; Heiman ML; Gehlert DR
J Pharmacol Exp Ther; 2000 Apr; 293(1):275-80. PubMed ID: 10734179
[TBL] [Abstract][Full Text] [Related]
16. Neuropeptide Y induced attenuation of catecholamine synthesis in the rat mesenteric arterial bed.
Westfall TC; Naes L; Gardner A; Yang CL
J Cardiovasc Pharmacol; 2006 Jun; 47(6):723-8. PubMed ID: 16810071
[TBL] [Abstract][Full Text] [Related]
17. Characterization of NPY receptor subtypes Y2 and Y7 in rainbow trout Oncorhynchus mykiss.
Larsson TA; Larson ET; Fredriksson R; Conlon JM; Larhammar D
Peptides; 2006 Jun; 27(6):1320-7. PubMed ID: 16359756
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological evaluation of 1229U91, a novel high-affinity and selective neuropeptide Y-Y1 receptor antagonist.
Hegde SS; Bonhaus DW; Stanley W; Eglen RM; Moy TM; Loeb M; Shetty SG; DeSouza A; Krstenansky J
J Pharmacol Exp Ther; 1995 Dec; 275(3):1261-6. PubMed ID: 8531090
[TBL] [Abstract][Full Text] [Related]
19. The peptide YY-preferring receptor mediating inhibition of small intestinal secretion is a peripheral Y(2) receptor: pharmacological evidence and molecular cloning.
Goumain M; Voisin T; Lorinet AM; Ducroc R; Tsocas A; Rozé C; Rouet-Benzineb P; Herzog H; Balasubramaniam A; Laburthe M
Mol Pharmacol; 2001 Jul; 60(1):124-34. PubMed ID: 11408607
[TBL] [Abstract][Full Text] [Related]
20. GPC receptors and not ligands decide the binding mode in neuropeptide Y multireceptor/multiligand system.
Lindner D; van Dieck J; Merten N; Mörl K; Günther R; Hofmann HJ; Beck-Sickinger AG
Biochemistry; 2008 Jun; 47(22):5905-14. PubMed ID: 18457425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
